Many pharma companies believe their biggest challenge with AI is the model.

In reality, the challenge is usually much simpler.

Data.

Most organizations store their most important information in different systems. Clinical data lives in one place. Patient support data lives somewhere else. Commercial teams use a different platform entirely.

Each system works well on its own.

The problem starts when the company tries to move information between them.

Insights slow down. Teams work from different versions of the truth. And the promise of AI starts to fade.

This is why many life sciences leaders are now focusing on something more fundamental.

Data infrastructure.

Pharma Systems Were Built in Pieces

Pharma technology stacks did not become fragmented by accident.

Each department adopted tools that solved their own problems.

Clinical teams needed systems for trials.
Medical affairs needed systems for HCP engagement.
Commercial teams needed tools for field operations.

Over time, those tools became the backbone of each department.

But they rarely connected cleanly.

The result is an organization where critical data is scattered across multiple environments. AI can analyze data inside those systems, but it struggles to create insights that move across the entire company.

This is where the concept of a Data Cloud begins to matter.

Data Cloud Connects Information Across Systems

A Data Cloud does something simple but powerful.

It connects data from many systems into one operational layer.

Instead of copying information from system to system, the platform creates a unified view of the organization’s data. This makes it possible for teams to work from the same information in real time.

Salesforce describes this shift clearly in its overview of Health Cloud for healthcare organizations, where patient data, engagement history, and care coordination can live in one environment instead of being spread across multiple systems.

When this model is applied to life sciences, the benefits multiply.

Clinical teams see patient insights faster.
Commercial teams understand treatment trends sooner.
Patient support teams gain visibility into engagement history.

Instead of data moving slowly between departments, the organization begins operating from one shared data foundation.

Life Sciences Platforms Are Built Around Unified Data

Another change happening across pharma technology stacks is the rise of industry-specific platforms.

General enterprise tools were never designed for life sciences workflows. Regulatory documentation, clinical collaboration, and patient programs all require specialized structures.

Platforms like Salesforce Life Sciences Cloud were built to support these workflows while connecting data across teams.

This creates something pharma organizations rarely had before.

Operational continuity.

Data generated in one part of the company can support decisions in another.

For example:

A clinical insight can inform medical education.
Medical education can shape field engagement.
Field engagement can improve patient support programs.

When these signals move across the organization, the company becomes far more responsive to real-world conditions.

AI Needs a Unified Data Layer

AI systems are powerful, but they depend heavily on the quality and structure of the data they analyze.

Salesforce notes that AI technologies in life sciences rely on large, connected datasets to generate meaningful insights and accelerate research and treatment development in its guide to AI in Life Sciences.

If data is fragmented, AI can still run.

But the results are limited.

The model only sees a small portion of the organization’s knowledge.

When a unified data layer exists, AI becomes far more useful.

Instead of analyzing isolated datasets, it can detect patterns across clinical outcomes, patient engagement, and operational performance.

That is when AI begins producing insights that actually change decisions.

Data Infrastructure Is Becoming a Leadership Priority

This shift is changing how technology leaders think about AI adoption.

Early conversations focused on adding new tools.

Now the focus is moving toward building the infrastructure those tools depend on.

Executives are starting to ask different questions.

Where does our data actually live?
Can teams access the same information?
Can insights move across departments?

These questions are less exciting than discussions about AI models.

But they determine whether those models produce real value.

Organizations that treat data infrastructure as a strategic asset are building the foundation for AI-driven operations.

Organizations that ignore it often struggle to move beyond early pilots.

The Companies Moving Fastest Are Fixing the Foundation

The life sciences companies seeing the most progress with AI share one thing in common.

They fixed their data layer first.

They unified data across teams.
They reduced system fragmentation.
They created platforms where insights can move quickly.

Only then did they scale AI across the organization.

That sequence matters.

AI multiplies the strength of the system it runs on.

If the foundation is weak, the results stay small.

If your organization is evaluating how to unify data across clinical, medical, and commercial systems, speak with CI Digital to learn how leading pharma companies are building data infrastructure that supports AI at scale.

You can also read our related article on Proper AI Usage in Pharma Requires Architectural Readiness to understand how system fragmentation slows innovation.